Literature DB >> 4655683

Metabolism of benzbromarone in man.

J Broekhuysen, M Pacco, R Sion, L Demeulenaere, M Van Hee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4655683     DOI： 10.1007/bf00562509

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  17 in total

1.  [On clinical experiences with 2-ethyl-3(4-hydroxy-3,5-dibrombenzoyl)-benzofuran ("Benzbromaron") in the therapy of gout and hyperuricemia].

Authors:  R Kotzaurek; E F Hueber
Journal:  Wien Med Wochenschr       Date:  1968-11-23

2.  [On the decrease of uric acid level in the plasma with benzbromarone].

Authors:  N Zöllner; G Stern; W Gröbner; W Dofel
Journal:  Klin Wochenschr       Date:  1968-12-15

3.  [Effect of benzbromaronum on the renal uric acid excretion in healthy persons].

Authors:  N Zöllner; W Dofel; W Gröbner
Journal:  Klin Wochenschr       Date:  1970-04-01

4.  [Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].

Authors:  N Zöllner; A Griebsch; J K Fink
Journal:  Dtsch Med Wochenschr       Date:  1970-11-27       Impact factor: 0.628

5.  [Analysis of the hypo-uricemic action of benzbromarone in 40 cases of gouty and non-gouty hyperuricemia].

Authors:  J P Famaey; G Vandenabeele
Journal:  J Belge Rhumatol Med Phys       Date:  1970 Jan-Feb

6.  [Changes in the serum concentration of uric acid under the effect of benzbromaronum].

Authors:  D P Mertz
Journal:  Munch Med Wochenschr       Date:  1969-02-28

7.  [Uricosuric and anti-gout action of certain benzofuran derivatives].

Authors:  F Delbarre; C Auscher; B Amor
Journal:  Presse Med       Date:  1965-11-13       Impact factor: 1.228

8.  [Research in the benzofuran series. 8. Transit of 2-ethyl-3-(4-hydroxybenzoyl)-benzofuran in man and animals].

Authors:  J Broekhuysen; J Bekaert; C Rozenblum; G Deltour
Journal:  Arch Int Pharmacodyn Ther       Date:  1965-11

9.  [Research on the benzofuran series. XXI. Inhibitory effect of phenolic benzofuran derivatives and of some analogues on rat liver xanthine oxidase in vitro].

Authors:  G Deltour; J Broekhuysen; M Ghislain; F Bourgeois; F Binon
Journal:  Arch Int Pharmacodyn Ther       Date:  1967-01

10.  IODINE-INDUCED HYPOTHYROIDISM DUE TO BENZIODARONE (CARDIVIX).

Authors:  M T HARRISON; A J CAMERON
Journal:  Br Med J       Date:  1965-03-27
View more
  9 in total

1.  Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles.

Authors:  I Walter-Sack; J X de Vries; A Ittensohn; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Variation of benzbromarone elimination in man--a population study.

Authors:  I Walter-Sack; U Gresser; M Adjan; I Kamilli; A Ittensohn; J X de Vries; E Weber; N Zöllner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Pharmacokinetics and biotransformation of benzbromarone in man.

Authors:  H Ferber; H Vergin; G Hitzenberger
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone.

Authors:  I Walter-Sack; J X de Vries; A Ittensohn; M Kohlmeier; E Weber
Journal:  Klin Wochenschr       Date:  1988-02-15

Review 5.  Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

6.  Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite.

Authors:  J X de Vries; I Walter-Sack; A Ittensohn; E Weber; H Empl; U Gresser; N Zöllner
Journal:  Clin Investig       Date:  1993-11

Review 7.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.

Authors:  Jeffrey N Miner; Philip K Tan; David Hyndman; Sha Liu; Cory Iverson; Payal Nanavati; David T Hagerty; Kimberly Manhard; Zancong Shen; Jean-Luc Girardet; Li-Tain Yeh; Robert Terkeltaub; Barry Quart
Journal:  Arthritis Res Ther       Date:  2016-10-03       Impact factor: 5.156

9.  Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2.

Authors:  Tetsuya Taniguchi; Koichi Omura; Keisuke Motoki; Miku Sakai; Noriko Chikamatsu; Naoki Ashizawa; Tappei Takada; Takashi Iwanaga
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.